about
PEGylation of protein-based MRI contrast agents improves relaxivities and biocompatibilitiesMetalloprotein-based MRI probesPorphyrin-Substituted H-NOX Proteins as High-Relaxivity MRI Contrast AgentsTailoring encodable lanthanide-binding tags as MRI contrast agentsDesign of ProCAs (protein-based Gd(3+) MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkersDesign of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkersMolecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agentsHER2 targeted molecular MR imaging using a de novo designed protein contrast agentProtein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging.Integration of Diverse Research Methods to Analyze and Engineer Ca-Binding Proteins: From Prediction to ProductionMultimodality and nanoparticles in medical imagingWhole animal imaging.Rigid Mn(II) chelate as efficient MRI contrast agent for vascular imaging.De novo design of Ln(III) coiled coils for imaging applications.Impact of biopolymer matrices on relaxometric properties of contrast agents.Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.Enhancing T1 magnetic resonance imaging contrast with internalized gadolinium(III) in a multilayer nanoparticleGeometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrastDesign of a modular protein-based MRI contrast agent for targeted application.Multivalent, high-relaxivity MRI contrast agents using rigid cysteine-reactive gadolinium complexesSilica microparticles as a solid support for gadolinium phosphonate magnetic resonance imaging contrast agents.Lumazine Synthase Protein Nanoparticle-Gd(III)-DOTA Conjugate as a T1 contrast agent for high-field MRIGRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRIReversible Folding of a β-Hairpin Peptide by a Metal-Chelating Amino Acid.Interaction of Biphenyl-Functionalized Eu(2+)-Containing Cryptate with Albumin: Implications to Contrast Agents in Magnetic Resonance ImagingStrategies for Target-Specific Contrast Agents for Magnetic Resonance ImagingRational design of a protein that binds integrin αvβ3 outside the ligand binding site.Self-assembling DNA quadruplex conjugated to MRI contrast agents.Size-Tunable Gd2O3@Albumin Nanoparticles Conjugating Chlorin e6 for Magnetic Resonance Imaging-Guided Photo-Induced Therapy.Magnetic resonance imaging (MRI) contrast agents for tumor diagnosis.Target binding improves relaxivity in aptamer-gadolinium conjugates.Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity.Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI.Gd(III)-induced Supramolecular Hydrogelation with Enhanced Magnetic Resonance Performance for Enzyme Detection.Metal toxicity and opportunistic binding of Pb(2+) in proteins.Protein-based MRI contrast agents for molecular imaging of prostate cancer.claMP Tag: a versatile inline metal-binding platform based on the metal abstraction peptide.High Relaxivity Gadolinium-Polydopamine Nanoparticles.Balancing the intermolecular forces in peptide amphiphiles for controlling self-assembly transitions.Metal-bound claMP Tag inhibits proteolytic cleavage.
P2860
Q24594884-002AB5E0-A1DA-4CB8-A0DA-CDE9B002A59FQ26849668-32552524-E154-4DA0-9C43-ADDE0EFE7AE4Q27676243-292B4450-7999-467F-BBFC-A6B2BF0015A6Q27683418-487144A1-C5DD-454C-89A7-83AF3855AD8FQ28235682-C30831D0-5CDB-4F1F-A222-3250E5971B2CQ28283802-884DCB92-04D1-4A45-A814-B3EAA40C307CQ28304646-EEA15AD6-6862-4CCF-80FC-F7282C1E42A6Q28477503-DE39548F-1956-4D9D-9B40-E07A4B2AD2B5Q30299954-C0E4FBA4-65AE-40A1-A996-05AAE9139A77Q30393133-D6DA86B2-2786-4438-984A-8E9FE689670BQ30407070-36B6B50A-8235-4C04-9113-8F130FF00F5CQ30411800-EF0386BF-A024-432B-B499-636AB04E6B5CQ30575244-0AC70DFD-0920-4FDF-8975-3AEA29489777Q30729722-0ABA8B2A-4E0C-4131-8E4F-84A3FFE96D8CQ31147094-F1135AD7-8AD3-472E-8DB0-A53E356F6A9EQ33847006-2D7CF38A-6787-47E8-AC2D-E91C5B23B0E3Q33887027-BA8E2E61-AD7D-42C8-9695-9BEDA21A007BQ34145477-B407811C-BD58-4AA8-A101-9B79D7CFD322Q34769835-6ACF57DD-2434-445F-A3EC-D9987D9F2A76Q35281165-C0E7540F-D858-4F4B-B251-1564B965FAB7Q36112041-49A8FE30-60C6-41EB-A1CD-27B2FE9AD99FQ36192560-31FDBD45-3C02-4286-96B5-09D88362135BQ36291569-D3E1DA15-8572-4412-8459-2F65811FFC4FQ36332528-315BE2DF-C061-4548-94F9-995FF872A25CQ36393668-74988B3B-6E20-4ECB-B3E5-D9944641BB4DQ36517070-8202AC57-F4B2-492D-AD22-80D6BA54F78CQ36974007-6CB64716-A4C7-419F-86E3-4AB99C7E76F8Q37133915-53801209-068F-4215-942F-A8B393A345E3Q37668581-B0752644-9E05-4DB6-98E8-2062317CF882Q38090392-58C5252B-F728-4CA1-B573-BEFEFFBC33A6Q38322510-92D14CEC-EAC8-401B-93A8-6191F7F2F0C3Q38716321-1248CD22-C5CD-4B50-926A-80FC44450D96Q41131993-0A598008-BEA1-4BFE-A4B5-AB5BEB08D5C7Q41196370-FE931CE7-B69D-43B5-ABB2-17A55067A373Q42416209-424DC1C7-8A40-4A67-96ED-977A08A435FAQ42530455-015B3BBD-4B81-41AF-B3A8-3A104305066FQ42970520-92AF2FC5-4244-450B-8B36-DCB6B1C5C4EBQ45939759-9E656984-B9DF-4A56-806C-8E344D94D89CQ48771490-8A571BDD-4052-4205-92C4-6C72C4648A28Q50624935-C02B7996-3ED4-4C67-A684-7F18CDAC8B61
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Rational design of protein-based MRI contrast agents
@en
type
label
Rational design of protein-based MRI contrast agents
@en
prefLabel
Rational design of protein-based MRI contrast agents
@en
P2093
P2860
P356
P1476
Rational design of protein-based MRI contrast agents
@en
P2093
Anna L Wilkins Maniccia
Eirik Krogstad
Fuqiang Zhao
Jenny J Yang
Jianhua Yang
Julian Johnson
Omar Zurkiya
P2860
P304
P356
10.1021/JA800736H
P407
P577
2008-06-25T00:00:00Z